Actively Recruiting
Phase 1 Study of AB122-Based Treatments for Adults With Advanced or Metastatic Solid Tumors
Led by Taiho Pharmaceutical Co., Ltd. · Updated on 2026-08-05
917
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase 1, open-label, multicenter platform study to evaluate the tolerability and safety of AB122 in patients with various advanced or metastatic solid tumors, including pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer, gastric cancer, alveolar soft part sarcoma, esophageal cancer, head and neck cancer, and biliary tract cancer. The study includes multiple cohorts based on tumor type and prior treatments, aiming to explore AB122 alone or in combination with other drugs. This non-randomized trial is designed to assess treatment effects across these groups.
CONDITIONS
Brief Title
AB122 Platform Study
Research Team
D
Drug Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here